FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Market Closed - Börse Stuttgart 09:12:09 24/05/2024 pm IST | ||
| 6.66 EUR | +7.94% |
|
| Current month | -30.55% | ||
| 1 month | -38.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 6.66 | +7.94% |
| 23/24/23 | 6.17 | -15.01% |
| 22/24/22 | 7.26 | +3.42% |
| 21/24/21 | 7.02 | -6.65% |
| 20/24/20 | 7.52 | -8.74% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 09:12 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MG01QD |
| ISIN | DE000MG01QD5 |
| Date issued | 11/03/2024 |
| Strike | 1,094 kr |
| Maturity | Unlimited |
| Parity | 3.25 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.46 € |
|---|---|
| Lowest since issue | 6.17 € |
| Spread | 0.03 € |
| Spread % | 0.46% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
928.8
DKK
Average target price
909.2
DKK
Spread / Average Target
-2.11%
- Stock Market
- Certificates
- Certificat
